Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of QRL-101 in ALS
NCT06714396Phase 1Completed
- Sponsor
- QurAlis
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing QRL-101 with Placebo (2 arms). Primary endpoints: QRL-101 plasma concentration at Day 10 and Strength-Duration Time Constant at Day 10. Started Nov 2024; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06714396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714396.